# Tamoxifen for the Prevention of Breast Cancer in High-Risk Women

> **NCT00002644** · PHASE3 · COMPLETED · sponsor: **Queen Mary University of London** · enrollment: 7154 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Tamoxifen Citrate 20Mg Tab
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT00002644
- **Lead sponsor:** Queen Mary University of London
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1994-01
- **Primary completion:** 2001-01
- **Final completion:** 2011-03-30
- **Target enrollment:** 7154 (ACTUAL)
- **Last updated:** 2024-12-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00002644

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00002644, "Tamoxifen for the Prevention of Breast Cancer in High-Risk Women". Retrieved via AI Analytics 2026-07-05 from https://api.ai-analytics.org/clinical/NCT00002644. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*